Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
ACCELA educational webinar: Unlocking Spatial Biology with RareCyte Orion
Mar 16, 2023
Experience Spatial Biology with Orion Multiplex Imaging. Orion is a benchtop, high...
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay
Mar 13, 2023
This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...
Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II
Mar 7, 2023
CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
New Kit for Bacterial analysis expands capability of Guava Muse flow cytometer
Feb 20, 2023
With the Guava Muse cell analyzer, you can now achieve highly quantitative results at a fraction of the price, effort,...
Differentation displacement in acute myeloid leukemia through enhancer activation
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Get more info
Brand profile
